Studies on Marble-Burying Behavior in Marble-Burying Behavior as an Animal Model of Obsessive-Compulsive Disorder

Michihiko Matsushta 1), Nobuaki Egashira 2), Ryoko Okuno 2), Satoko Harada 2), Junya Tsukada 1), Yoshiaki Kiyohara 1), Shozo Chidori 1), Naoki Uchida 1), Kenichi Mishima 2), Katsunori Iwasaki 2), Michihiro Fujisara 2), Ryoji Nishimura 1)

1) Department of Psychiatry, Faculty of Medicine, Fukuoka University
2) Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University

Abstract: In the present study, we examined the involvement of serotonin (5-hydroxytryptamine, 5-HT) 1A receptor in marble-burying behavior, which has been considered to be an animal model of obsessive-compulsive disorder (OCD). 8-OH-DPAT, a full 5-HT 1A receptor agonist, inhibited marble-burying behavior without affecting the locomotor activity at a dose of 3 mg/kg (i.p.). Similarly, fluvoxamine (30, 60 mg/kg, p.o.), paroxetine (1, 3 mg/kg, p.o.) and milnacipran (60 mg/kg, p.o.) inhibited marble-burying behavior. The inhibitory effect of 8-OH-DPAT or paroxetine was antagonized by WAY-100635 (3 mg/kg, i.p.), a 5-HT 1A receptor antagonist, whereas those effects of fluvoxamine or milnacipran was not antagonized by WAY-100635. On the other hand, haloperidol (0.1 mg/kg, i.p.) significantly reduced the number of buried marbles. However, these drugs at the same dose significantly reduced locomotor activity and impaired motor coordination in the rota-rod test. The low-dose haloperidol (0.01 mg/kg, i.p.) or fluvoxamine (10 mg/kg, p.o.) did not significantly reduce the number of buried marbles, but the low-dose combination of fluvoxamine and haloperidol inhibited the marble-burying behavior without affecting the locomotor activity. These findings suggest that combining antipsychotic with selective serotonin reuptake inhibitor (SSRI) may be a clinically useful drug in the treatment of intractable obsessive compulsive disorder.

Key words: Marble-burying behavior, Obsessive-compulsive disorder, selective serotonin reuptake inhibitor (SSRI), antipsychotic drug, 5-HT 1A receptor